Decitabine: all 314 studies that test it

Page 1 of 4. Open to participants first (62), then studies with results posted, then the rest; newest registration first within each.

• Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AMLNot yet recruitingNCT07867626Phase 2
• Hydrochloroquinine & Decitabine With Venetoclax in AMLNot yet recruitingNCT07814339Phase 1
• A Study of VABu Conditioning Regimen in Allo-HSCT for AML PatientsNot yet recruitingNCT07762508Not applicable
• Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal CancerNot yet recruitingNCT07691632Phase 2
• ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDSNot yet recruitingNCT07617363Phase 1
• AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCLNot yet recruitingNCT07594899Phase 2
• Evaluating the Safety and Efficacy of Decitabine in the Treatment of XMEN PatientsNot yet recruitingNCT07555405Phase 4
• Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AMLNot yet recruitingNCT07511062Phase 1
• Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML PatientsRecruitingNCT07507760Phase 2
• Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML PatientsNot yet recruitingNCT07505160Phase 2
• Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCLNot yet recruitingNCT07493330Phase 1/2
• Modulation of Stem Cell Differentiation in Individuals With High Risk Clonal HaematopoiesisNot yet recruitingNCT07435636Phase 2
• A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.RecruitingNCT07389239Phase 1/2
• FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid LeukemiaRecruitingNCT07283094Phase 1
• Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative NeoplasmsRecruitingNCT07148947Phase 2
• Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized TrialRecruitingNCT07101588Phase 4
• Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease MarkerRecruitingNCT07060001Phase 2
• VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCTNot yet recruitingNCT07052422Phase 2/3
• A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid LeukemiaRecruitingNCT07012044Phase 1
• Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）Not yet recruitingNCT07007767Phase 2
• A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)RecruitingNCT07006025Phase 1
• Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck CancerRecruitingNCT06997094Phase 1
• Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT06972641Phase 2/3
• Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of RelapseRecruitingNCT06928662Phase 1/2
• Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic SyndromesRecruitingNCT06923488Phase 1/2
• Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLRecruitingNCT06803693Phase 2
• Venetoclax and Decitabine in R/R T-ALLRecruitingNCT06712121Phase 2
• A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)RecruitingNCT06561074Phase 2
• VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDSRecruitingNCT06536959Phase 2
• Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic CancerRecruitingNCT06454448Phase 1/2
• Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor OlutasidenibRecruitingNCT06445959Phase 1/2
• Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLNot yet recruitingNCT06441097Phase 2
• A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid LeukemiaRecruitingNCT06401603Phase 1
• Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALLRecruitingNCT06393985Phase 2
• Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid MalignanciesRecruitingNCT06383572Phase 1/2
• Avapritinib With Decitabine in Patients With SM-AHNRecruitingNCT06327685Phase 1
• Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MRNot yet recruitingNCT06297772Phase 3
• Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AMLRecruitingNCT06156579Phase 2
• Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell TransplantRecruitingNCT06129734Phase 1/2
• Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDSRecruitingNCT06046313Phase 2
• Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian CancerRecruitingNCT05983276Phase 2
• Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage MesotheliomaRecruitingNCT05960773Phase 2
• Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCTNot yet recruitingNCT05669079Phase 3
• Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDSRecruitingNCT05636514Phase 1
• Genotype-guided Treatment in DLBCLRecruitingNCT05351346Phase 3
• Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell LymphomaRecruitingNCT05348213Phase 2
• Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid TumorsRecruitingNCT05320640Phase 1/2
• A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)RecruitingNCT05190471Phase 1
• Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AMLRecruitingNCT05184842Phase 2Results posted
• Outcomes of Patients After Allo-HSCT With Decitabine and NACNot yet recruitingNCT04945096Phase 3
• Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent FailureRecruitingNCT04905810Phase 2
• The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.RecruitingNCT04514081Phase 2
• Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsRecruitingNCT04282187Phase 2
• Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic SyndromeRecruitingNCT04245397Phase 1
• Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin LymphomaRecruitingNCT04233294Phase 2
• 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid MalignanciesRecruitingNCT04187703Early Phase 1
• Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeRecruitingNCT03661307Phase 1/2
• SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin LymphomaRecruitingNCT03250962Phase 2
• Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingNCT03013998Phase 2/3
• Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory MalignanciesRecruitingNCT02961101Phase 1/2
• Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AMLRecruitingNCT02781883Phase 2
• Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)RecruitingNCT01515527Phase 2
• Decitabine for Poor Graft Function Post Allo-HSCTCompletedNCT05907499Phase 3Results posted
• A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)TerminatedNCT05835011Phase 2Results posted
• Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell TransplantTerminatedNCT05799079Phase 2Results posted
• Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid LeukemiaCompletedNCT04277442Phase 1Results posted
• Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative DiseaseCompletedNCT04146038Phase 2Results posted
• Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDSCompletedNCT04055844Phase 2Results posted
• GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid LeukemiaTerminatedNCT04051996Phase 2Results posted
• A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive ChemotherapyCompletedNCT03941964Phase 3Results posted
• DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT03358719Phase 1Results posted
• Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AMLCompletedNCT03306264Phase 3Results posted
• Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)CompletedNCT03303339Phase 1/2Results posted
• Epigenetic Reprogramming in Relapse/Refractory AMLCompletedNCT03263936Phase 1Results posted
• Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal CarcinomasTerminatedNCT03233724Phase 1/2Results posted
• Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid LeukemiaCompletedNCT03226418Phase 2Results posted
• Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating AgentTerminatedNCT03146871Phase 2Results posted
• Safety and Activity of Digoxin With Decitabine in Adult AML and MDSTerminatedNCT03113071Phase 1/2Results posted
• Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT03092674Phase 2/3Results posted
• Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT03063203Phase 2Results posted
• Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer PatientsCompletedNCT03019003Phase 1Results posted
• Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT02996474Phase 1/2Results posted
• Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDSCompletedNCT02921061Phase 1/2Results posted
• Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid LeukemiaActive, not recruitingNCT02890329Phase 1Results posted
• Decitabine and Talazoparib in Untreated AML and R/R AMLCompletedNCT02878785Phase 1/2Results posted
• Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE TrialCompletedNCT02664181Phase 2Results posted
• Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1Active, not recruitingNCT02650986Phase 1/2Results posted
• Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 MutationTerminatedNCT02634827Phase 2Results posted
• A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)CompletedNCT02632721Phase 1/2Results posted
• Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AMLTerminatedNCT02532010Phase 2Results posted
• A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDSCompletedNCT02488408Phase 1/2Results posted
• Prospective Study of Patients With Thrombocytopenia Following HSCTCompletedNCT02487563Phase 3Results posted
• Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)CompletedNCT02269280Phase 2Results posted
• Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid LeukemiaCompletedNCT02257138Phase 1/2Results posted
• Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative NeoplasmCompletedNCT02121418Not applicableResults posted
• Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML PatientsCompletedNCT02109744Phase 1/2Results posted
• Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)CompletedNCT02103478Phase 1/2Results posted
• Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02085408Phase 3Results posted
• Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT02029417Phase 2Results posted
• Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)TerminatedNCT02010645Phase 2Results posted

← Decitabine overview